Wuxi AppTec CoWUXIF 84 Buyback Yield % is 0.00 as of Jul. 03, 2026. GuruFocus rates WUXIF with a GF Score™ of 84/100 and a GF Value™ of $14.57 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 89 Medical Diagnostics & Research companies, Wuxi AppTec Co ranks worse than 1123594.38% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Wuxi AppTec Co's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WUXIF vs TMO, DHR, IDXX: Buyback Yield % Comparison
For the Diagnostics & Research subindustry, Wuxi AppTec Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuxi AppTec Co Buyback Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Wuxi AppTec Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Wuxi AppTec Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuxi AppTec Co (WUXIF) has a Buyback Yield % of 0.00 as of Jul. 03, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Wuxi AppTec Co and its competitors. According to the industry distribution chart, Wuxi AppTec Co ranks #999999 out of 89 companies in the Medical Diagnostics & Research industry.
Is Wuxi AppTec Co's Buyback Yield % too high?
Wuxi AppTec Co's current Buyback Yield % is 0.00. Based on the distribution chart, Wuxi AppTec Co ranks #999999 out of 89 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Wuxi AppTec Co has a GF Score™ of 84/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wuxi AppTec Co's Buyback Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Wuxi AppTec Co ranks #999999 out of 89 companies for Buyback Yield %. This places Wuxi AppTec Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Diagnostics & Research company?
A good Buyback Yield % depends on the Medical Diagnostics & Research industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Wuxi AppTec Co and its competitors. Wuxi AppTec Co's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuxi AppTec Co stock overvalued right now?
Based on GuruFocus' analysis, Wuxi AppTec Co (WUXIF) is currently considered Significantly Overvalued. The stock's GF Value™ is $14.57, compared to a current price of $21.19 — trading 45.4% above its estimated fair value. The current Buyback Yield % is 0.00. Wuxi AppTec Co's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Wuxi AppTec Co (WUXIF), the current Buyback Yield % is 0.00 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wuxi AppTec Co (WUXIF) Overvalued in 2026?
Based on GuruFocus' analysis, Wuxi AppTec Co stock appears to be overvalued.
The current stock price of $21.19 is trading 45.4% above its estimated GF Value™ of $14.57.
GuruFocus considers Wuxi AppTec Co to be Significantly Overvalued.
Key valuation signals for WUXIF:
Buyback Yield %: 0.00
GF Value™: $14.57 vs. price of $21.19 (45.4% above fair value)
No single metric tells the full story. See the WUXIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, and manufacturing spectrum for small molecule drugs, development of computer software and databases as well as consulting services for combinatorial chemistry and pharmaceuticals. The services offered by the company include drug research and development testing, clinical research services, an end-to-end CRDMO platform for peptide, oligonucleotide, and small molecules, and integrated biology services and solutions for drug discovery. The company's reportable segments are WuXi Chemistry, which derives maximum revenue, WuXi Testing, WuXi Biology, and Others. Geographically, it derives key revenue from the United States of America, followed by PRC, Europe, and other regions.
84GF Score
Get the complete analysis for WUXIF
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WUXIF has been successfully added to your 
